IRIS
LAUDICELLA, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.494
EU - Europa 1.826
AS - Asia 1.782
SA - Sud America 663
AF - Africa 51
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.820
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.415
SG - Singapore 831
BR - Brasile 575
IE - Irlanda 421
SE - Svezia 386
IT - Italia 377
CN - Cina 335
HK - Hong Kong 278
DE - Germania 159
VN - Vietnam 104
PL - Polonia 77
GB - Regno Unito 74
IN - India 71
FR - Francia 69
FI - Finlandia 51
RU - Federazione Russa 46
AR - Argentina 37
CA - Canada 37
AT - Austria 30
MX - Messico 29
ZA - Sudafrica 25
BE - Belgio 23
JP - Giappone 23
LT - Lituania 22
NL - Olanda 20
ID - Indonesia 18
TR - Turchia 18
ES - Italia 17
IQ - Iraq 13
BD - Bangladesh 11
IR - Iran 11
EC - Ecuador 10
UA - Ucraina 10
VE - Venezuela 10
AE - Emirati Arabi Uniti 9
MA - Marocco 9
PE - Perù 9
UZ - Uzbekistan 9
PY - Paraguay 8
AZ - Azerbaigian 7
CZ - Repubblica Ceca 7
IL - Israele 7
CO - Colombia 6
GE - Georgia 5
PK - Pakistan 5
CH - Svizzera 4
CL - Cile 4
KW - Kuwait 4
NO - Norvegia 4
PT - Portogallo 4
BG - Bulgaria 3
BY - Bielorussia 3
EG - Egitto 3
GR - Grecia 3
JM - Giamaica 3
JO - Giordania 3
KE - Kenya 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
PA - Panama 3
PH - Filippine 3
SA - Arabia Saudita 3
UY - Uruguay 3
AL - Albania 2
AU - Australia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
LU - Lussemburgo 2
PR - Porto Rico 2
RO - Romania 2
SN - Senegal 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
BW - Botswana 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
Totale 6.820
Salva come PNG Salva come JPEG
Città #
Ashburn 421
Dublin 419
Chandler 413
Singapore 354
Nyköping 288
Hong Kong 278
Dallas 260
Beijing 137
Messina 113
Los Angeles 98
The Dalles 89
Princeton 74
Munich 70
Warsaw 70
Medford 61
São Paulo 50
Bremen 37
Ho Chi Minh City 36
Des Moines 35
Redondo Beach 34
New York 33
Buffalo 32
Rome 28
Hyderabad 27
Helsinki 26
Brussels 23
Hanoi 21
Nuremberg 21
Moscow 20
Jacksonville 19
Palermo 18
Santa Clara 18
Dearborn 17
Frankfurt am Main 17
Johannesburg 17
Seattle 17
Turku 17
London 16
Stockholm 16
Vienna 16
Montreal 14
Mumbai 14
Boston 13
Jakarta 13
Jinan 13
Porto Alegre 13
Rio de Janeiro 13
Tianjin 13
Tokyo 13
Boardman 12
Brooklyn 12
Denver 12
Brasília 11
Campinas 11
Curitiba 11
Ann Arbor 10
Atlanta 10
Kameido 10
Nanjing 10
Poplar 10
Pune 10
Belo Horizonte 9
Bexley 9
Genoa 9
Mexico City 9
Milan 9
Tashkent 9
Amsterdam 8
Chennai 8
Dong Ket 8
Lappeenranta 8
Phoenix 8
San Francisco 8
Toronto 8
Baku 7
Cagliari 7
Hangzhou 7
Nanchang 7
São José do Rio Preto 7
Wilmington 7
Ankara 6
Betim 6
Biên Hòa 6
Charlotte 6
Chicago 6
Haiphong 6
Lima 6
Orem 6
Ottawa 6
Redwood City 6
Shenyang 6
Tel Aviv 6
West Jordan 6
Wroclaw 6
Barcellona Pozzo di Gotto 5
Catania 5
Düsseldorf 5
Feira de Santana 5
Fortaleza 5
Goiânia 5
Totale 4.270
Salva come PNG Salva come JPEG
Nome #
Artificial intelligence in molecular imaging: from machine to deep learning 160
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 141
[68 Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177 Lu]DOTATOC PRRT: The “Theragnomics” Concept 141
18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis" 140
PRRT Retreatments: Renal Function Evaluation 138
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 130
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 129
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 128
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 121
18F-FACBC in prostate cancer: A systematic review and meta-analysis 121
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience 119
Clinico-laboratory response and haematological toxicity in patients undergoing therapy with 223RA-dichloride 118
Safety, effectiveness and haematological toxicity of 223Radichloride: a single Centre experience 118
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 117
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 115
Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience 111
COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings 110
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 107
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 106
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 104
PRRT retreatments: renal function evaluation 104
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma 104
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 99
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 97
Renal Function Evaluation in PRRT Retreatments 97
Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation 95
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 91
Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience 89
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 87
Artifcial intelligence applications in SSTR targeted PET/CT images: prediction of response assessment in GEP-NETs undergoing PRRT with [177Lu]DOTATOC 87
Radiomics Analysis of Brain [18 F]FDG PET/CT to Predict Alzheimer’s Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis 86
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas 85
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 84
Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination 82
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 80
The utility of dual time-point FET-PET/CT in recurrence assessment of glioma patients 80
Correction to: 18F-FMISO PET imaging: insights over MRI in patients with glioma (Clinical and Translational Imaging, (2020), 8, 1, (3-10), 10.1007/s40336-019-00353-0) 77
Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging 75
PET/MR in neuro-oncology: is it ready for prime-time? 75
Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers 73
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study 73
Artificial intelligence applications in 68Ga-DOTA PETICT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC 73
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature 73
Sars-cov-2 persistence: data summary up to q2 2020 72
Molecular imaging of pancreatic neoplasms 72
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome 70
68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement 69
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics 66
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 65
[18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review 64
Prognostic insights of molecular imaging in cardiac sarcoidosis 64
Malignant cutaneous melanoma: Updates in PET imaging 63
Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 62
Emerging applications of imaging in glioma: focus on PET/MRI and radiomics 61
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging 60
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients 59
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 59
Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer 58
FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature 57
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI 53
The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence Also in Comparison with MRI 52
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT 51
From bench to bedside: highlights from the International Dialogue on Ovarian Cancer 50
Response prediction to PRRT in progressing and metastatic GEP-NET undergoing restaging 68Ga-DOTA PETICT: A preliminary multicenter radiomics study 50
Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals 47
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature 46
[11C]Choline PET/CT in a Patient with Prostate Cancer Biochemical Recurrence Showing Two Suspicious Findings in the Breast and Liver 46
An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics 42
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics 42
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 41
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 41
PET Imaging in Gliomas: Clinical Principles and Synergies with MRI 40
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 40
[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond 39
Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study 39
A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors 38
Monitoring of cardiac transthyretin amyloid load by [Tc-99m]DPD scintigraphy: is it the end of the semi-quantitative evaluation? 37
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study 36
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 34
Correction: PSMA‑positive prostatic volume prediction with deep learning based on T2‑weighted MRI 33
Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients 32
A Review of Advances in Molecular Imaging of Rheumatoid Arthritis: From In Vitro to Clinic Applications Using Radiolabeled Targeting Vectors with Technetium-99m 31
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review 31
The role of PET radiomic features in prostate cancer: a systematic review 31
Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs) 31
PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI 30
[18F]PSMA‑1007 PET/CT‑based radiomics may help enhance the interpretation of bone focal uptakes in hormone‑sensitive prostate cancer patients 29
Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer? 29
ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork 28
Reply to Perera Molligoda Arachchige AS [1] 28
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer 28
Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features? 28
Artificial intelligence in molecular imaging: from machine to deep learning 27
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers 26
Unspecic bone uptakes in PSMA PET for prostate cancer: why do they matter? 25
Artificial Intelligence and Statistical Models for the Prediction of Radiotherapy Toxicity in Prostate Cancer: A Systematic Review 25
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years 24
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer 24
null 23
[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature 20
Totale 6.908
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.805
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.805
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021137 0 0 0 0 0 13 12 14 43 27 17 11
2021/2022464 6 30 4 22 31 13 27 34 6 54 35 202
2022/20231.387 119 196 70 107 91 140 17 89 482 16 36 24
2023/2024369 41 39 22 33 43 50 13 31 9 32 16 40
2024/20252.168 12 59 45 75 153 64 154 317 510 184 287 308
2025/20262.248 450 366 384 424 556 68 0 0 0 0 0 0
Totale 7.040